4 results about "Sulfonyl" patented technology

The present invention is to provide an imidazolidinedione derivative and oxazolidinedione derivative represented by the following general Formula (I) having the chymase and/or tryptase inhibition activity [wherein R<1 >and R<2 >are the same or different, and denote a lower alkyl group or a phenyl group, or R<1 >and R<2 >are taken together to form a ring, R<3 >denotes an optionally substituted naphthyl group or heterocyclic group, A denotes oxygen or NR<4 >(R<4 >is hydrogen or optionally substituted lower alkyl group), or NB<2>R<5 >(R<5 >is aryl group, and B<2 >is carbonyl group or sulfonyl group), and B<1 >denotes a carbonyl group or a sulfonyl group], or a pharmaceutically acceptable salt thereof.

The invention discloses amphoteric polyurethane. Firstly, diisocyanate, hydroxyl-terminated polymer, a cation chain extender and a catalyst are mixed to be uniform, terminated isocyanate group polyurethane prepolymer containing tertiary amine is prepared through a prepolymerization reaction, after that, aromatic compound micromolecules containing hydroxyl-terminated and sulfonyl are taken as an anion chain extender, and amphoteric polyurethane containing tertiary amine and sulfonyl simultaneous is prepared and obtained through an end capping reaction. The invention further discloses the application of amphoteric polyurethane serving as a retanning agent for reducing free formaldehyde in leather, a neutralizing agent and water are added into amphoteric polyurethane to prepare amphoteric polyurethane emulsion which can serve as the retanning agent rightly. The retanning agent can enable the removal rate of free formaldehyde in leather to reach 80% or above when being used in the retanning process of leather.

Substituted N—[N-(sulphonylphenyl)sulfonyl-prolyl]-phenylalanine derivatives of the present invention are antagonists of the VLA-4 integrin and are useful in the treatment, prevention and suppression of diseases mediated by VLA-4-binding and cell adhesion and activation. Moreover, the compounds of the present invention demonstrate significant receptor occupancy of VLA-4 bearing cells after oral administration and are suitable for once-, twice-, or thrice-a-day oral administration. This invention also relates to compositions containing such compounds and methods of treatment using such compounds.